---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-004478"
form_type: "8-K"
ticker: "RXST"
cik: "0001111485"
company_name: "RxSight, Inc."
filed_at: "2025-01-13T23:59:59+00:00"
generated_at: "2026-05-28T02:46:14.156834+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# RxSight reports preliminary Q4/FY2024 rev ~$40.2M/$139.9M, +41%/+57% YoY; guides 2025 rev $185-197M

## Summary
- Q4 2024 revenue ~$40.2M (+41% YoY); FY2024 ~$139.9M (+57% YoY).
- LAL procedure volume Q4 29,069 (+61% YoY); FY 98,055 (+79% YoY).
- LDD installed base 971 as of Dec 31 (+46% YoY); cash & investments $237.2M.
- 2025 revenue guidance $185M-$197M (32-41% growth); gross margin 71-73%.
- Preliminary results subject to audit; audited FY2024 & unaudited Q4 due Feb 2025.

## SEC filing metadata
- accession: 0000950170-25-004478
- form_type: 8-K
- ticker: RXST
- cik: 0001111485
- company_name: RxSight, Inc.
- filed_at: 2025-01-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1111485/000095017025004478/0000950170-25-004478-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1111485/000095017025004478/rxst-20250112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-004478
- JSON: https://secwatch.observer/filing/0000950170-25-004478.json
- Plain text: https://secwatch.observer/filing/0000950170-25-004478.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.